Antibodies to fibrin-bound tissue-type plasminogen activator in systemic lupus erythematosus are associated with Raynaud's phenomenon and thrombosis - PubMed (original) (raw)
Comparative Study
Antibodies to fibrin-bound tissue-type plasminogen activator in systemic lupus erythematosus are associated with Raynaud's phenomenon and thrombosis
M Salazar-Paramo et al. Lupus. 1996 Aug.
Abstract
Fibrinolysis triggered by t-PA bound to fibrin is one of the main antithrombotic mechanisms. Defects in the fibrinolytic system-decreased tissue-type plasminogen activator (t-PA) activity and elevated levels of plasminogen activator inhibitor (PAI-1), in patients with SLE have been associated with an increased tendency to thrombosis. In the present study, 43 patients with SLE fulfilling the ACR criteria for the disease, were studied for the presence of autoantibodies to fibrin-bound t-PA, i.e. the physiological active form of this plasminogen activator. A solution of 200 IU/ml of t-PA was incubated with solid-phase fibrin prepared as previously described (Anal Biochem 1986; 153; 201-210). Sera diluted 1:50 were incubated with fibrin-bound t-PA, the plates were then washed, and bound immunoglobulins were detected using a polyvalent peroxidase-labeled goat anti-human Ig. Plates coated with fibrin alone were used as controls. Sera were considered positive when A490/630 obtained with normal human sera in two independent test was greater than the mean plus 2 SD. Eleven of 43 (26%) SLE sera demonstrated antibody reactivity against fibrin-bound t-PA. Within the anti-t-PA positive group there was a higher proportion of SLE patients with severe Raynaud's phenomenon and thrombotic events when compared to the anti-t-PA negative group: 36% vs 6% and 18% vs 6% respectively. These results suggest that autoantibodies to fibrin-bound t-PA could play a role in the pathogenesis of vascular disease in some SLE patients.
Similar articles
- Antibodies to fibrin bound tissue type plasminogen activator in systemic sclerosis.
Fritzler MJ, Hart DA, Wilson D, García-De La Torre I, Salazar-Páramo M, Vázquez-Del Mercado M, Senécal JL, Loyau S, Anglés-Cano E. Fritzler MJ, et al. J Rheumatol. 1995 Sep;22(9):1688-93. J Rheumatol. 1995. PMID: 8523346 - Autoantibodies to receptor induced neoepitopes of fibrinolytic proteins in rheumatic and vascular diseases.
Dominguez M, Cacoub P, Garcia de la Torre I, Piette TJ, Salazar-Paramo M, Godeau P, Angleés-Cano E. Dominguez M, et al. J Rheumatol. 2001 Feb;28(2):302-8. J Rheumatol. 2001. PMID: 11246666 - Serum antibodies to distinct epitopes of the tissue-type plasminogen activator (t-PA) in patients with systemic lupus erythematosus.
Ruiz-Arguelles A, Angles-Cano E, Perez-Romano B, Ruiz-Arguelles GJ, Deleze M, Alarcon-Segovia D, Gaussem P. Ruiz-Arguelles A, et al. Am J Hematol. 1995 Jun;49(2):109-14. doi: 10.1002/ajh.2830490203. Am J Hematol. 1995. PMID: 7539580 - Thrombosis in systemic lupus erythematosus: role of impaired fibrinolysis.
Dhillon PK, Adams MJ. Dhillon PK, et al. Semin Thromb Hemost. 2013 Jun;39(4):434-40. doi: 10.1055/s-0033-1334484. Epub 2013 Mar 16. Semin Thromb Hemost. 2013. PMID: 23504607 Review.
Cited by
- Cardiovascular disease in latin american patients with systemic lupus erythematosus: a cross-sectional study and a systematic review.
Amaya-Amaya J, Sarmiento-Monroy JC, Caro-Moreno J, Molano-González N, Mantilla RD, Rojas-Villarraga A, Anaya JM. Amaya-Amaya J, et al. Autoimmune Dis. 2013;2013:794383. doi: 10.1155/2013/794383. Epub 2013 Nov 3. Autoimmune Dis. 2013. PMID: 24294522 Free PMC article. - Involvement of tissue plasminogen activator in onset and effector phases of experimental allergic encephalomyelitis.
Lu W, Bhasin M, Tsirka SE. Lu W, et al. J Neurosci. 2002 Dec 15;22(24):10781-9. doi: 10.1523/JNEUROSCI.22-24-10781.2002. J Neurosci. 2002. PMID: 12486171 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous